Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report

@article{Howard2013SizeOB,
  title={Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report},
  author={James Philip Howard and Alexandra Nowbar and Darrel P. Francis},
  journal={Heart},
  year={2013},
  volume={99},
  pages={1579 - 1587}
}
Objective 30 mm Hg drops in office systolic blood pressure are reported in trials of renal denervation, but ambulatory reductions are much smaller. This disparity is assumed to have a physiological basis and also be present with antihypertensive drugs. Design We examine this office-ambulatory discrepancy through meta-analysis of drug and denervation trials, categorising by trial design. Patients (studies) 31 drug trials enrolling 4121 patients and 23 renal denervation trials enrolling 720… Expand
Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis
TLDR
While poor quality unblinded studies provide evidence that renal denervation using catheter-based systems is effective in reducing systolic and diastolic blood pressure in resistant hypertension, the largest randomised controlled trial to date (SYMPLICITY HTN-3) failed to demonstrate any benefit. Expand
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
TLDR
This trial did not demonstrate a benefit of renal artery denervation on reduction in ambulatory BP in either the 24-h or day and night periods compared with sham. Expand
Renal artery sympathetic denervation: observations from the UK experience
TLDR
In 253 patients treated with RDN, office BP fell by 22/9 mmHg, though little response was seen in the lowermost quartile of starting blood pressure, and aldosterone antagonist use did not affect response. Expand
Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial
TLDR
The INSPiRED trial will generate long-term efficacy and safety data, identify the subset of treatment-resistant hypertensive patients responsive to RDN, provide information on cost-effectiveness, and inform guideline committees and health policy makers. Expand
Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation
TLDR
The nontrivial magnitude of these apparent blood pressure reductions with perfectly ineffective intervention (placebo) illustrates that efficacy explorations of novel therapies for hypertension, once safety is established, should be performed with a randomized, appropriately controlled, and blinded design. Expand
Impact of number of prescribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation
TLDR
Visit-to-visit variability in BP is dramatically larger in patients with more background medications prescribed, if this is due to variable adherence, then future RDN trials, needing to detect smaller effect sizes, would benefit from measures to guarantee adherence. Expand
Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – a randomized controlled trial
TLDR
It is concluded that spironolactone is more effective than RDN to reduce 24-h SBP and 24-H DBP in patients with resistant hypertension and should be the fourth antihypertensive drug to prescribe if deemed well tolerated’ in all patients withresistant hypertension. Expand
Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study.
  • H. Sievert, J. Schofer, +6 authors Meital Cohen-Mazor
  • Medicine
  • EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2015
TLDR
Renal artery denervation with the Vessix System reduced both office and ambulatory BP at six months in patients with resistant hypertension, with favourable results for renal artery safety and renal function. Expand
Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: A meta-analysis.
TLDR
The totality of blinded, randomized placebo-controlled data shows that renal denervation is safe and provides genuine reduction in blood pressure for at least 6 months post-procedure. Expand
Renal Denervation in Patients With Uncontrolled Hypertension and Confirmed Adherence to Antihypertensive Medications
TLDR
The authors present their experience of the use of catheter‐based RDN as part of routine clinical care in two specialist hypertension clinics and found that there was a significant change in clinic systolic BP and clinic diastolic BP 6 months postprocedure. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 114 REFERENCES
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
TLDR
Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors. Expand
Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial
TLDR
In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension. Expand
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT-EXT): a randomized, double-blind, placebo-controlled trial
TLDR
Spironolactone treatment in patients with resistant arterial hypertension leads to a significant decrease of both systolic and diastolic blood pressure. Expand
Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up.
TLDR
The efficacy and safety of renal sympathetic denervation by using a standard EP catheter during long-term FU (12 months) with a larger group of patients with drug-resistant hypertension was evaluated. Expand
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
TLDR
Catheter-based renal denervation causes substantial and sustained blood-pressure reduction, without serious adverse events, in patients with resistant hypertension, in a proof-of-principle trial of therapeutic renal sympathetic denervation. Expand
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
TLDR
All the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure, indicating that the benefit is explained by blood pressure reduction itself. Expand
Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension
TLDR
RDN reduced office BP and improved relevant aspects of ambulatory BP monitoring, commonly linked to high cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affected office BP in pseudoresistant hypertension. Expand
Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis
TLDR
The results showed that treatment-induced reduction in blood pressure is both smaller for the 24-h average than for the office systolic and diastolic blood pressure and smaller for night-time than for daytime average diastolics blood pressure. Expand
Clinical trials with ambulatory blood pressure monitoring: fewer patients needed?
TLDR
It is concluded that parallel-group trials focusing on the average blood pressure over 24 h, rather than on conventionally measured blood pressure, cannot economise on sample size and require more--not fewer--patients than studies of only the conventional or average 24 h blood pressure. Expand
Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience
TLDR
Catheter-based renal denervation seems an attractive novel minimally invasive treatment option in patients with resistant hypertension, with a low risk of serious adverse events. Expand
...
1
2
3
4
5
...